ADAM17 selectively activates the IL‐6 trans‐signaling/ERK MAPK axis in KRAS‐addicted lung cancer
Year: 2019
Type: article
Abstract: Oncogenic KRAS mutations are major drivers of lung adenocarcinoma (LAC), yet the direct therapeutic targeting of KRAS has been problematic. Here, we reveal an obligate requirement by oncogenic KRAS for the ADAM17 protease in LAC. In genetically engineered and xenograft (human cell line and patient‐derived) KrasG12D‐driven LAC models, the specific blockade of ADAM17, including with a non‐toxic prodomain inhibitor, suppressed tumor burden by reducing cellular proliferation. The pro‐tumorigenic activity of ADAM17 was dependent upon its threonine phosphorylation by p38 MAPK, along with the preferential shedding of the ADAM17 substrate, IL‐6R, to release soluble IL‐6R that drives IL‐6 trans‐signaling via the ERK1/2 MAPK pathway. The requirement for ADAM17 in KrasG12D‐driven LAC was independent of bone marrow‐derived immune cells. Furthermore, in KRAS mutant human LAC, there was a significant positive correlation between augmented phospho‐ADAM17 levels, observed primarily in epithelial rather than immune cells, and activation of ERK and p38 MAPK pathways. Collectively, these findings identify ADAM17 as a druggable target for oncogenic KRAS‐driven LAC and provide the rationale to employ ADAM17‐based therapeutic strategies for targeting KRAS mutant cancers. Oncogenic KRAS mutations are associated with one‐third of lung adenocarcinoma (LAC) cases, yet the downstream molecular events that facilitate KRAS‐mediated tumorigenesis in the lung remain unresolved. This study reveals an obligate requirement by oncogenic KRAS for the ADAM17 protease in LAC. Oncogenic KRAS mutations are associated with one‐third of lung adenocarcinoma (LAC) cases, yet the downstream molecular events that facilitate KRAS‐mediated tumorigenesis in the lung remain unresolved. This study reveals an obligate requirement by oncogenic KRAS for the ADAM17 protease in LAC.
Source: EMBO Molecular Medicine
Authors: Mohamed I Saad, Sultan Alhayyani, Louise McLeod, Liang Yu, Mohammad Alanazi, Virginie Deswaerte, Ke Tang, Thierry Jarde, Julian A Smith, Zdenka Prodanovic, Michelle D Tate, Jesse J Balic, D Neil Watkins, Jason E Cain, Steven Bozinovski, Elizabeth Algar, Tomohiro Kohmoto, Hiromichi Ebi, Walter Ferlin, Christoph Garbers, Saleela Ruwanpura, Irit Sagi, Stefan Rose‐John, Brendan J Jenkins
Institutions: Hudson Institute of Medical Research, Monash University, Monash Medical Centre, Monash Health, Garvan Institute of Medical Research, The Kinghorn Cancer Centre, RMIT University, Aichi Cancer Center, Aichi Cancer Center Research Institute, Tokushima University, Nagoya University, Light Chain Bioscience (Switzerland), Otto-von-Guericke-Universität Magdeburg, Weizmann Institute of Science, Christian-Albrechts-Universität zu Kiel
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $4,200
Awards: Develop novel therapeutics against KRAS mutant cancer by regulating PI3K and ERK signal(Fostering Joint International Research), G2329248152, G2693665147, G4051792487, G4988265143, G5172661196, Identification of interleukin-6 trans-signalling as a novel target for therapeutic approaches to lung cancer, 多層的遺伝子発現情報解析と機能解析の統合による胃癌の新規治療標的同定と治療法開発, Development of target therapy against KRAS mutant lung cancer stratified by EMT status.
OpenAlex ID: W2920126503
